Claims for Patent: 7,560,276

Summary for Patent: 7,560,276

Title:	Soft tissue repair and regeneration using postpartum-derived cells
Abstract:	Cells derived from postpartum tissue having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.
Inventor(s):	Harmon; Alexander M. (Clinton, NJ), Harris; Ian Ross (Belle Mead, NJ), Kihm; Anthony J. (Princeton, NJ), Mistry; Sanjay (Bedminster, NJ), Messina; Darin J. (Somerville, NJ), Seyda; Agnieszka (New Brunswick, NJ), Yi; Chin-Feng (Hillsborough, NJ), Gosiewska; Anna (Skillman, NJ)
Assignee:	Ethicon, Incorporated (Somerville, NJ)
Application Number:	10/877,009
Patent Claims:	1. A method of stimulating tissue infiltration in a soft tissue defect in a patient in need thereof, said method comprising (a) contacting mammalian umbilical cord tissue that is substantially free of blood with a composition comprising dispase and at least one of hyaluronidase and collagenase, thereby yielding isolated cells; (b) optionally expanding said isolated cells in culture; (c) placing said isolated or expanded, isolated cells onto a scaffold, thereby yielding a scaffold comprising cells; and then (d) administering to said soft tissue defect of said patient said scaffold comprising cells; wherein said isolated or expanded, isolated cells are capable of self-renewal and differentiation; wherein said isolated or expanded, isolated cells do not express CD117; and wherein said isolated or expanded, isolated cells exhibit increased expression relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell of an endogenous gene encoding oxidized low density lipoprotein receptor 1, an endogenous gene encoding interleukin 8, and an endogenous gene encoding reticulon 1; and wherein said scaffold comprising cells stimulates tissue infiltration into said soft tissue defect. 2. The method of claim 1 wherein said isolated cells or said expanded, isolated cells require L-valine for growth and are capable of growth in about 5% to about 20% oxygen. 3. The method of claim 1 wherein said isolated cells or said expanded, isolated cells comprise the following characteristics: potential for at least about 40 doublings in culture; attachment and expansion on a coated or uncoated tissue culture vessel, wherein said coated tissue culture vessel comprises a coating of gelatin, laminin, collagen, polyornithine, vitronectin, or fibronectin; production of vimentin and alpha-smooth muscle actin; and production of CD10, CD13, CD44, CD73, and CD90. 4. The method of claim 1 wherein the isolated cells or the expanded, isolated cells express each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-A,B,C. 5. The method of claim 1 wherein the isolated cells or the expanded, isolated cells do not express any of CD31, CD34, CD45, CD117, CD141, or HLA-DR,DP,DQ, as detected by flow cytometry. 6. The method of claim 1 wherein the tissue comprises blood vessels. 7. The method of claim 1 wherein said step of administering comprises implanting, injecting, or engrafting said scaffold.

Details for Patent 7,560,276

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2023-06-27
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2023-06-27
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2023-06-27
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2023-06-27